Biocon Limited has invested Rs 315,34,42,850 in its wholly owned subsidiaries Biocon Biosphere Limited and Biocon Pharma Limited through the acquisition of Optionally Convertible Redeemable ...

Biocon Ltd has finalised the purchase of Optionally Convertible Redeemable Non-Cumulative Preference Shares (OCRPS) from its subsidiaries for ₹315 crore.

Biocon Ltd has completed the acquisition of OCRPS in its wholly owned subsidiaries. It bought 11.53 crore OCRPS of Biocon Biosphere Ltd for ₹115.34 crore (₹20 crore in cash, ₹95.34 crore via earlier ...

More recently, Mazumdar-Shaw has opened doors for KGI students in the U.S. by supporting scholarships. Late last year, Mazumdar-Shaw also hosted President Abousalem at Biocon’s headquarters in India.

Biocon secures USFDA approval for generic Liraglutide, entering the lucrative US obesity treatment market with gSaxenda.

Motilal Oswal is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 450 in its research report dated 3, 2026.

Biocon Ltd has received US FDA approval for its complex formulation Liraglutide Injection 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pens (gSaxenda). The drug-device combination is indicated ...

By Rishika Sadam Feb 16 (Reuters) - Biocon is aiming for high-double-digit percentage revenue growth as the Indian pharmaceutical firm prepares to launch generic versions of weight-loss drugs globally ...

Biocon’s insulin copycat aspart hit another roadblock as the FDA issued a complete response letter (CRL), saying the Malaysia production facility still must undergo a pre-approval inspection to ...

Biocon said that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its complex formulation Liraglutide Injection.

The biosimilar fracas targeting AbbVie’s megablockbuster Humira is taking shape. But to Biocon Biologics CEO Shreehas Tambe, the battle doesn’t solely revolve around market share. Humira, also known ...

Biocon Biologics has been positioning itself to become a global player in biosimilar drugs. Viatris, a longtime partner to Biocon, is charting a course for its future that does not include biosimilars ...